. 2022 Aug 18;43(2):230–244. doi: 10.1093/asj/sjac225

Table 3.

Reduction in Symptom Number by Cohort and Visit and Presence of Cutibacterium acnes at Baseline

Cohort	Parameter	Visit	Cutibacterium acnes		P-value^a
Cohort	Parameter	Visit	Yes (n = 22)	No (n = 28)	P-value^a
Cohort A	50% or more reduction in symptom number	3-6 weeks	14 (66.7)	17 (63.0)	1.0000
	50% or more reduction in symptom number	6 months	18 (81.8)	18 (66.7)	0.3328
	80% or more reduction in symptom number	3-6 weeks	6 (28.6)	11 (40.7)	0.5442
	80% or more reduction in symptom number	6 months	13 (59.1)	10 (37.0)	0.1567
Cohort B	50% or more reduction in symptom number	3-6 weeks	6 (85.7)	13 (46.4)	0.0964
	50% or more reduction in symptom number	6 months	3 (60.0)	9 (37.5)	0.6221
	80% or more reduction in symptom number	3-6 weeks	2 (28.6)	10 (35.7)	1.0000
	80% or more reduction in symptom number	6 months	1 (20.0)	5 (20.8)	1.0000

Values are n (%). Results are limited to patients with at least 1 reported symptom at baseline based on solicited symptoms listed on the Case Report Form. ^aP-value from Fisher’s exact test, testing the null hypothesis that the true percentages of patients with reduction in symptom number are equal for the 2 groups vs the alternative hypothesis that these percentages are not equal.